Candel Therapeutics Inc.
CADL
We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens an…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$99M
▲ +30.8% YoY
Op. Margin
–
ROIC
-51.49%
▲ +4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$70M
▼ -43.9% YoY
Op. Cash Flow (TTM)
-$69M
▼ -41.8% YoY
Net Debt
-$202M
Net Cash Position
Cash & Equiv.
$203M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CADL
Held by ETFs
CADL is in 16 US ETFs. The largest of them, with CADL's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.18%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
State Street SPDR S&P Kensho New Economies Composite ETFKOMP0.09%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.04%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.04%of the fund
Candel Therapeutics (CADL) in three numbers
Questions about Candel Therapeutics
Is Candel Therapeutics a high-quality business?
Candel Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$202M, and its weakest is return on capital at -51.5%. The Quality tab shows every check against its target.
Does Candel Therapeutics (CADL) pay a dividend?
No. Candel Therapeutics (CADL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CADL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CADL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.